QIVIGY LogoQIVIGY

Contact Us

Get Support for the journey ahead

Hypothetical patient.

Kedrion Biopharma provides support for eligible people receiving QIVIGY®.

Contact us to learn more about our copay assistance program and how you may qualify.

QIVIGY copay program

You may be eligible to receive up to $10,000 per calendar year to use on out-of-pocket costs for QIVIGY.

Visit QIVIGY.medmonk.com for full Terms and Conditions

Contact us for assistance with QIVIGY, coverage programs, or reimbursement support:

Phone

Call the
Kedrion information line at
888-262-8040

Email

Email Kedrion at
reimbursementsupport@
medmonk.com

Commonly asked questions

Here are a few commonly asked questions about QIVIGY. Talk to your doctor for any additional questions you may have regarding your treatment needs.

Q:

How active can I be while taking QIVIGY?

Question tail

Some people may find it helpful to stay active while taking QIVIGY. Talk to your doctor about how you are feeling so that, together, you can come up with an exercise routine that works best for you.

Q:

Is there anything I should bring to my infusion?

Question tail

You should bring water to make sure you stay hydrated before your infusion and dress comfortably.1

Since your infusion time may vary, it’s important that you have what you need to be comfortable. You can bring something to help you pass the time, whether it’s a tablet to watch a show or play a game, headphones to listen to music or a podcast, a book, a laptop to catch up on work, or a cozy pillow and blanket to help you relax.

Q:

What are the most common side effects of QIVIGY?

Question tail

The most common side effect of QIVIGY is headaches. Other common side effects include fatigue, nausea, infusion-related reaction, positive direct Coombs test result suggesting the immune system is attacking the body’s red blood cells, sinus inflammation, dizziness, and diarrhea.1

Q:

Is QIVIGY safe for people who are pregnant?

Question tail

It is not known whether QIVIGY can cause fetal harm in people who are pregnant as there are no data available to determine the risk. What is known is that immune globulins can cross the placenta through maternal blood circulation. It is advised QIVIGY be given to people who are pregnant only if clearly needed.1

Q:

Can children use QIVIGY?

Question tail

QIVIGY is approved for adults with PI. Its safety and effectiveness in children has not been established.1

Patient resources

Patient BrochurePatient Brochure

Connect with patient advocacy organizations

The following list of patient advocacy groups can help support you on your journey with PI.

Immune Deficiency Foundation (IDF)

The Immune Deficiency Foundation (IDF) improves the diagnosis, treatment, and quality of life for every person affected by PI. The IDF fosters a community that is connected, engaged, and empowered through advocacy, education, and research.

Learn more
Jeffrey Modell Foundation

The Jeffrey Modell Foundation is a global nonprofit dedicated to early diagnosis, meaningful treatments and, ultimately, cures through basic and clinical research, physician and patient education, public awareness, government advocacy, patient support, newborn screening, and genetic sequencing.

Learn more
International Patient Organisation for Primary Immunodeficiencies (IPOPI)

The International Patient Organisation for Primary Immunodeficiencies (IPOPI) is an international nonprofit organization and the leading worldwide advocate for people with PI.

Learn more
Immunoglobulin National Society (IgNS)

The Immunoglobulin National Society (IgNS) is a professional organization dedicated to the advancement of Ig therapy practice across clinical indications and areas of practice.

Learn more

Ig, immunoglobulin; PI, primary immunodeficiency.

Get started with QIVIGY
Important Safety Information

What is QIVIGY®?

QIVIGY (immune globulin intravenous, human-kthm) is an immune globulin (Ig) liquid used to treat adults with primary humoral immunodeficiency.

Important safety information

QIVIGY may cause:

  • Blood clots (thrombosis). Blood clots may occur in people taking Ig intravenous (IGIV) products, including QIVIGY. You may be at greater risk for blood clots if you are older, sit or lie for long periods, have a clotting problem or history of blood clots, take estrogen, have a central catheter, have thick blood, and/or if you have other conditions that put you at risk for cardiovascular disease. Blood clots may occur even if you do not have any of these risk factors. Your healthcare provider will monitor you for signs and symptoms of blood clotting.
  • Impaired kidney function or kidney failure. IGIV products have been associated with kidney dysfunction and damage, kidney failure, and death. You may be at greater risk for kidney failure if you have kidney disease, diabetes, are over 65, are seriously dehydrated, overweight, have certain infections like sepsis, have a condition that causes abnormal proteins in your blood, or take drugs that may damage your kidneys. Your healthcare provider will monitor your kidney function before and periodically after your first infusion.

Do NOT use QIVIGY if:

  • You have a history of severe hypersensitivity or a history of allergic reactions to human Ig. Tell your healthcare provider if you have had a serious reaction to other medicines that contain human Ig or ask if you are not sure.
  • You have an immunoglobulin A (IgA) deficiency, have antibodies to IgA, and have a hypersensitivity or a history of allergic reactions. Tell your healthcare provider if you have an IgA deficiency or ask if you are not sure.

WARNINGS AND PRECAUTIONS

  • Severe allergic reactions may occur. People with IgA deficiency who have antibodies against IgA may be at greater risk of these reactions.
  • You could experience higher-than-normal levels of protein in your blood, thick blood, or low sodium (salt) in your blood. This may prevent your blood from flowing easily and possibly lead to blood clots.
  • Brain swelling called aseptic meningitis syndrome may occur with IGIV products, especially if you receive a high dose or a rapid infusion.
  • Blood damage called hemolysis and hemolytic anemia can develop after treatment with QIVIGY. Your healthcare provider will monitor you for signs and symptoms.
  • Swelling of the lungs may occur following treatment. Your healthcare provider will monitor you for signs of lung damage.
  • QIVIGY is made from human blood and may contain infectious agents, eg, viruses and, theoretically, the Creutzfeldt-Jakob disease agent.
  • Be sure to tell your healthcare provider about your recent history of vaccinations. Live vaccines for diseases like measles, mumps, rubella, and varicella may not work as well while receiving QIVIGY. Tell your healthcare provider that you are taking QIVIGY before you receive any vaccination.

ADVERSE REACTIONS

The most common side effects of QIVIGY were headache, fatigue, infusion-related reaction, positive direct Coombs test result suggesting the immune system is attacking the body's red blood cells, nausea, sinus inflammation, dizziness, and diarrhea. During treatment with QIVIGY, be sure to tell your healthcare provider about any unusual symptoms you experience, as they may indicate a possible side effect.

To report SUSPECTED ADVERSE REACTIONS, contact Kedrion Biopharma Inc. at 1-855-3KDRION (1-855-353-7466) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information for complete prescribing details, including Boxed Warning.

Reference: 1. QIVIGY [prescribing information]. Kedrion Biopharma Inc.; 2025.